Skip to main content
    F

    Fortress Biotech Inc (FBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.71
    -0.17 (-9.04%)

    Market Cap: $62.70M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Fortress Biotech Inc (FBIO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Fortress Biotech reported revenue of $63.26M for the fiscal year ended Dec 31, 2025, up 9.7% from the year before. That year, net income was -$32.91M with a net margin of -52.0%, operating cash flow was -$65.78M and free cash flow was -$65.78M. The quarter ended Sep 30, 2026 had revenue of $19.16M and net income of -$8.25M.

    Revenue and Margins

    The net margin was -52.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $45.98M, a compound annual rate of 3.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$63.26M+9.7%66.9%-111.0%-52.0%
    Dec 2024$57.67M-31.8%63.8%-191.4%-209.5%
    Dec 2023$84.51M+11.6%72.9%-168.4%-182.4%
    Dec 2022$75.74M+10.1%59.4%-268.8%-282.4%
    Dec 2021$68.79M+50.9%53.4%-274.1%-239.6%
    Dec 2020$45.60M+24.5%68.0%-206.7%-225.8%
    Dec 2019$36.63M+36.3%71.2%-302.5%-277.5%
    Dec 2018$26.88M+55.9%77.2%-446.4%-528.0%
    Dec 2017$17.25M-62.5%78.8%-520.7%-578.9%
    Dec 2016$45.98MN/A97.5%-77.2%-155.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$63.26M$57.67M$84.51M$75.74M$68.79M$45.60M$36.63M$26.88M$17.25M$45.98M
    Cost of revenue$20.92M$20.88M$22.89M$30.77M$32.08M$14.59M$10.53M$6.13M$3.66M$1.13M
    Gross profit$42.34M$36.80M$61.62M$44.97M$36.71M$31.00M$26.10M$20.76M$13.59M$44.85M
    Research and development$11.90M$56.88M$106.07M$134.88M$128.87M$64.11M$81.33M$87.38M$52.49M$40.67M
    Operating income-$70.22M-$110.38M-$142.34M-$203.56M-$188.54M-$94.27M-$110.82M-$120.00M-$89.80M-$35.49M
    Net income-$32.91M-$120.86M-$154.15M-$213.91M-$164.83M-$102.98M-$101.66M-$141.94M-$99.84M-$71.29M
    EBITDA-$46.98M-$103.18M-$132.29M-$191.77M-$178.28M-$84.51M-$84.39M-$115.70M-$86.47M-$33.59M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$19.16M$18.72M$16.04M$16.08M$17.63M$16.41M$13.14M$15.16M$14.63M$14.86M$13.03M$19.95M
    Gross profit$13.28M$12.57M$9.82M$10.64M$11.87M$11.47M$8.35M$10.48M$10.16M$9.13M$7.03M$17.70M
    Operating income-$7.19M-$10.01M-$7.74M-$4.62M-$6.81M-$36.47M-$22.32M-$23.93M-$22.09M-$27.79M-$36.57M-$19.61M
    Net income-$8.25M$602.00K$137.16M-$5.40M$8.83M-$11.65M-$24.69M-$26.31M-$26.69M-$28.82M-$39.02M-$28.98M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $52.42M by $26.96M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$185.55M$144.22M$167.53M$294.30M$396.50M$333.41M$226.42M$140.99M$245.95M$170.73M
    Current assets$123.84M$90.37M$117.02M$230.43M$346.46M$266.15M$156.25M$111.21M$183.18M$109.63M
    Cash and equivalents$79.38M$57.26M$80.93M$178.27M$305.74M$233.35M$136.86M$65.51M$94.95M$88.29M
    Total liabilities$123.36M$145.87M$165.94M$244.28M$170.63M$136.41M$153.89M$121.25M$125.45M$87.76M
    Short-term debt$0$3.25M$5.52M$2.95M$812.00K$0$7.22M$19.08M$13.23M$2.03M
    Long-term debt$52.42M$57.96M$60.86M$91.73M$42.94M$59.81M$82.43M$60.42M$39.21M$22.53M
    Shareholder equity$49.87M$22.74M$22.54M$41.72M$108.67M$100.34M$26.21M$1.85M$52.57M$38.49M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$280.21M$316.71M$356.87M$185.55M$181.41M$159.90M$178.07M$144.22M$127.08M$145.69M$164.65M$167.53M
    Total liabilities$103.19M$110.63M$154.50M$123.36M$116.22M$122.51M$145.59M$145.87M$139.82M$160.28M$168.58M$165.94M
    Cash and equivalents$152.19M$196.58M$255.84M$79.38M$86.22M$74.39M$91.34M$57.26M$58.85M$76.20M$83.77M$80.93M
    Shareholder equity$160.00M$164.14M$162.21M$49.87M$55.86M$43.92M$22.25M$22.74M$21.16M$17.88M$23.02M$22.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$65.78M-$80.19M-$128.22M-$179.40M-$116.54M-$83.68M-$94.96M-$98.85M-$81.31M-$45.81M
    Capital expenditures$0$15.00M$63.00K$2.71M$4.57M$1.93M$2.35M$7.08M$648.00K$6.37M
    Free cash flow-$65.78M-$95.19M-$128.29M-$182.12M-$121.11M-$85.61M-$97.31M-$105.93M-$81.95M-$52.18M
    Dividends paid$664.00K$4.71M$8.77M$8.78M$8.78M$6.75M$2.56M$2.34M$299.00K$0
    Share repurchasesN/AN/AN/AN/AN/A$70.00K$427.00K$0$2.80M$0
    Investing cash flow$10.12M-$15.00M-$2.10M-$22.93M$40.51M-$7.16M$20.10M$18.82M-$40.22M-$6.06M
    Financing cash flow$77.44M$70.64M$32.74M$75.32M$148.99M$172.41M$146.71M$50.65M$150.38M$42.91M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.20M-$59.28M$203.85M-$12.54M-$6.11M-$27.56M-$19.56M-$12.91M-$20.06M-$21.84M-$25.39M-$34.94M
    Capital expenditures$7.00KN/A$0$0$0$0$0$0$0$0$0$28.00K
    Free cash flow-$6.20MN/A$203.85M-$12.54M-$6.11M-$27.56M-$19.56M-$12.91M-$20.06M-$21.84M-$25.39M-$34.96M
    Last 12 quarters

    Frequently Asked Questions About FBIO

    What is Fortress Biotech's annual revenue?

    Fortress Biotech reported revenue of $63.26M for the fiscal year ended Dec 31, 2025.

    How fast is Fortress Biotech's revenue growing?

    Revenue was up 9.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -5.8%.

    Is Fortress Biotech profitable?

    No. Fortress Biotech reported net income of -$32.91M for the fiscal year ended Dec 31, 2025, with a net margin of -52.0%.

    How much free cash flow does FBIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$65.78M minus capital expenditures of $0 produced free cash flow of -$65.78M.

    How much debt does Fortress Biotech have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $52.42M, short-term debt of $0 and cash and equivalents of $79.38M.